Thyrocare Technologies Limited — Important, 23-01-2025: Financial Result Updates

Thyrocare Technologies Limited has announced a board meeting to discuss its financial results for the quarter and nine months ended December 31, 2024.

The company reported consolidated revenue from operations of ₹152.55 crore for the quarter, marking a year-over-year increase of approximately 24.10%. The growth can be attributed to an uptick in demand for diagnostic and pathological services, bolstered by the recent acquisitions of Polo Labs and Vimta Labs, which expanded its service offerings.

Net profit for the quarter stood at ₹29.59 crore, compared to ₹51.91 crore in the same period last year, indicating a decline in profitability. The decrease reflects increased operational costs, notably from heightened depreciation expenses driven by revised useful life estimates for testing machines, which raised depreciation by ₹4.75 crore. Consequently, the earnings per share (EPS) came in at ₹3.47.

Operational costs rose significantly, primarily due to expansion-related expenses and adjustments to staff costs, highlighting the company’s proactive positioning to enhance service capabilities amidst growing competition.

On the balance sheet, Thyrocare continues to maintain a robust financial position, with prudent cash flow management despite pressures on profitability. The strategic focus remains on operational efficiency and continued expansion through acquisitions, which should help mitigate immediate cost challenges.

Overall, given the revenue growth, strategic acquisitions, and ongoing efforts to optimize operational efficiencies, a hold insight is advisable, awaiting further clarity on the impact of rising costs and competitive pressures in the sector.